ReviewJournal of gastrointestinal oncology2026
Impacts of neoadjuvant therapy on subsequent surgical difficulty, safety, and outcomes in locally advanced rectal cancer: a narrative review.
Review in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Locally advanced rectal cancer (LARC) is standardly treated with neoadjuvant therapy, but clinical concerns regarding its adverse impacts on subsequent surgery have led to poor guideline adherence worldwide. This review systematically synthesized literature to evaluate the effects of neoadjuvant therapy on surgical difficulty, procedural outcomes, postoperative complications, and surgery-related oncological outcomes. Methods: A thorough search of PubMed and Web of Science was performed for literature published from January 2000 to February 2026. Clinical trials, real-world studies, meta-analyses, systematic reviews, and other review articles related to locally advanced rectal cancer, neoadjuvant therapy, and surgery were examined. Key Content and Findings: Neoadjuvant chemoradiotherapy (NACRT) was not associated with significant adverse effects on subsequent surgery compared with upfront surgery (UFS), and improved sphincter-preservation rates via tumor downstaging, especially for patients with low rectal cancer. Advances in minimally invasive surgery may further improve surgical outcomes after NACRT. Additionally, different radiotherapy modalities, prolonged intervals between radiotherapy completion and surgery, intensified chemotherapy regimens, and immunotherapy combinations did not significantly increase surgical burden or major perioperative complications, with some regimens even improving oncological outcomes. Conclusions: Neoadjuvant therapy is surgically safe for LARC without increasing perioperative risks, although the impact of radiotherapy remains somewhat controversial. The long-term oncologic outcomes and subgroup-specific effects of neoadjuvant therapy combined with surgery require further high-quality evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.